Aristotle University Of Thessaloniki (AUTH)
Μία τυχαιοποιημένη, διπλά τυφλή, ελεγχόμενη με εικονικό φάρμακο μελέτη της επίδρασης της λιραγλουτίδης στην αρτηριακή πίεση υπερτασικών ασθενών με σακχαρώδη διαβήτη τύπου 2
Abstract
dc:descriptionIncidence of type 2 diabetes mellitus (T2DM) has been continually rising during the past years as a result of sedentary lifestyle and increasing prevalence of obesity. Available therapeutic options for disease management are constantly expanding by the addition of new pharmacologic categories with pleiotropic actions beyond glycaemic control. In this regard glucagon-like peptide 1 (GLP-1) receptor agonists such as liraglutide are injectable antidiabetic therapies with side benefits for patients because they reduce body weight as well as risk of cardiovascular adverse events in patients with established atherosclerotic disease. In addition, they confer renoproctive properties by ameliorating progression of albuminuria. Patients with type 2 diabetes suffer from many comorbidities amongst which arterial hypertension is highly prevalent and associated with increased incidence of cardiovascular events and mortality. Aim of the present thesis is to assess the effect of liraglutide, a long acting GLP-1 receptor agonist, on blood pressure of hypertensive patients with type 2 diabetes by means of a double blind, randomised controlled trial. Patients with inadequate glycaemic control (haemoglobin A1c 7-10%) and pre-hypertension or stage 1 hypertension were deemed eligible and were randomised to five-week treatment with liraglutide or placebo. To ascertain the effect of liraglutide on blood pressure and heart rate 24-h ambulatory monitoring was utilised, whilst a parallel mechanistic study was developed to elucidate the effect of liraglutide on renal sodium handling. Sixty two patients with a mean age of 60.2 years participated in the trial and were equally randomised to liraglutide and placebo arms. All participants received background therapy with metformin, whilst 35.5% and 14.5% of them received concomitant therapy with sulphonylurea and pioglitazone respectively. Apart from improving glycaemic control liraglutide reduced mean 24-h systolic blood pressure compared with placebo by 5.73 mmHg [95% confidence interval (CI) –9.81 to –1.65], nevertheless it had a neutral effect on mean 24-h diastolic blood pressure (mean difference compared with placebo –1.42 mmHg; 95% CI –4.25 to 1.40). Moreover, treatment with liraglutide lead to an increase in mean 24-h heart rate by 6.16 beats/min (95% CI 3.25 to 9.07) compared with placebo. In patients treated with liraglutide no increase in 24-h urine sodium excretion was noted (–2.94 mmol/24-h; 95% CI –45.20 to 39.33). Finally, five-week treatment with liraglutide lead to an absolute reduction in haemoglobin A1c levels by 0.47% (95% CI –0.86 to –0.08); nevertheless body weight remained essentially unchanged (mean difference compared with placebo –0.20 kg; 95% CI –1.46 to 1.06). In conclusion, based on 24-h ambulatory monitoring short-term treatment with liraglutide had a favourable effect on systolic blood pressure which was though accompanied by a positive chronotropic response. The antihypertensive effect of liraglutide could not be explained by natriuresis or change in body weight.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Liakos, Aris
- Λιάκος, Άρης
Subjects
dc:subject × 12- Σακχαρώδης διαβήτης τύπου 2
- Αρτηριακή υπέρταση
- Λιραγλουτίδη
- Αγωνιστές των υποδοχέων του γλυκαγονόμορφου πεπτιδίου 1
- Type 2 diabetes mellitus
- Arterial hypertension
- liraglutide
- Glucagon-like peptide 1 (GLP-1) receptor agonists
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
dc:rights- Statement dc:rights
-
- BY
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/45592